Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...

Together, these results point to a clinically meaningful synergy between pelareorep and checkpoint inhibitors like ...

Together, these results point to a clinically meaningful synergy between pelareorep and checkpoint inhibitors like ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics ...